英唐智控(300131.SZ):公司代理的顯示驅動芯片主要應用在汽車和手機領域
格隆匯7月13日丨有投資者向英唐智控(300131.SZ)提問,“貴公司目前在顯示驅動ic芯片領域有哪些產品、技術、解決方案以及代理了哪些產品?貴公司和新思的合作是什麼樣的?”
英唐智控回覆稱,公司代理的顯示驅動芯片主要應用在汽車和手機領域。代理的汽車顯示驅動芯片來自新思;代理的手機顯示驅動芯片來自豪威科技。2023年4月,公司與新思簽訂合作協議,雙方利用各自品牌及資源優勢,擬在新思的A款DDIC產品展開合作。新思將其A款DDIC產品在中國境內的生產、供應鏈及銷售權授予許可給本公司及下屬子公司,授權期限10年。具體內容請查看公司在巨潮資訊網披露的相關公吿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.